Francesco Iemolo

Francesco Iemolo

Auto-generated profile, based on publicly available information

Francesco Iemolo

CNR-IBIM: Institute of Biomedicine and Molecular Immunology “A. Monroy”, Via Ugo la Malfa n.153, Palermo, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2009 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
FIFrancesco Iemolo
Francesco Iemolo
GDGiovanni Duro
Giovanni Duro
CRClaudia Rizzo
Claudia Rizzo
LCLaura Castiglia
Laura Castiglia
VHVladimir Hachinski
Vladimir Hachinski
Calogero CarusoCalogero Caruso
Calogero Caruso
The concept of Vascular Dementia (VaD) has been recognized for over a century, but its definition and diagnostic criteria remain unclear. Conventional definitions identify the patients too late, miss subjects with cognitive impairment short of dementia, and emphasize consequences rather than causes, the true bases for treatment and prevention. We should throw out current diagnostic categories and describe cognitive impairment clinically and according to commonly agreed instruments that document the demographic data in a standardized manner and undertake a systematic effort to identify the underlying aetiology in each case. Increased effort should be targeted towards the concept of and criteria for Vascular Cognitive Impairment and Post-Stroke Dementia as well as for genetic factors involved, especially as these categories hold promise for early prevention and treatment.

6 September 2011 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
CBCaterina Bono
Caterina Bono
Domenico NuzzoDomenico Nuzzo
Domenico Nuzzo
GAGiuseppe Albeggiani
Giuseppe Albeggiani
CZCarmela Zizzo
Carmela Zizzo
DFDaniele Francofonte
Daniele Francofonte
GDGiovanni Duro
Giovanni Duro
Anderson-Fabry disease (FD) is caused by a deficit of the α-galactosidase A enzyme which leads to the accumulation of complex sphingolipids, especially globotriaosylceramide (Gb3), in all the cells of the body, causing the onset of a multi-systemic disease with poor prognosis in adulthood. In this article, we describe two alternative methods for screening the GLA gene which codes for the α-galactosidase A enzyme in subjects with probable FD in order to test analysis strategies which include or rely on initial pre-screening.

8 June 2012 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
Antonio PisaniAntonio Pisani
Antonio Pisani
MIMassimo Imbriaco
Massimo Imbriaco
CZCarmela Zizzo
Carmela Zizzo
GAGiuseppe Albeggiani
Giuseppe Albeggiani
PCPaolo Colomba
Paolo Colomba
GDGiovanni Duro
Giovanni Duro
Background: Fabry disease (FD) is a hereditary metabolic disorder caused by the partial or total inactivation of a lysosomal hydrolase, the enzyme α-galactosidase A (GLA). This inactivation is responsible for the storage of undegraded glycosphingolipids in the lysosomes with subsequent cellular and microvascular dysfunction. The incidence of disease is estimated at 1:40,000 in the general population, although neonatal screening initiatives have found an unexpectedly high prevalence of genetic alterations, up to 1:3,100, in newborns in Italy, and have identified a surprisingly high frequency of newborn males with genetic alterations (about 1:1,500) in Taiwan. Case presentation: We describe the case of a 40-year-old female patient who presented with transient ischemic attack (TIA), discomfort in her hands, intolerance to cold and heat, severe angina and palpitations, chronic kidney disease. Clinical, biochemical and molecular studies were performed. Conclusions: Reported symptoms, peculiar findings in a renal biopsy – the evidence of occasional lamellar inclusions in podocytes and mesangial cells – and left ventricular (LV) hypertrophy, which are considered to be specific features of FD, as well as molecular evaluations, suggested the diagnosis of a classical form of FD. We detected four mutations in the GLA gene of the patient: -10C>T (g.1170C>T), c.370-77_-81del (g.7188-7192del5), c.640-16A>G (g.10115A>G), c.1000-22C>T (g.10956C>T). These mutations, located in promoter and intronic regulatory regions, have been observed in several patients with manifestations of FD. In our patient clinical picture showed a multisystemic involvement with early onset of symptoms, thus suggesting that these intronic mutations can be found even in patients with classical form of FD.

7 January 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
FIFrancesco Iemolo
Francesco Iemolo
FPFederica Pizzo
Federica Pizzo
GAGiuseppe Albeggiani
Giuseppe Albeggiani
CZCarmela Zizzo
Carmela Zizzo
PCPaolo Colomba
Paolo Colomba
GDGiovanni Duro
Giovanni Duro
Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date, more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo onset occur rarely.

1 July 2012 in Clinical Biochemistry
Verified
Journal Article
Closed access
PCPaolo Colomba
Paolo Colomba
ANAntonia Nucera
Antonia Nucera
CZCarmela Zizzo
Carmela Zizzo
GAGiuseppe Albeggiani
Giuseppe Albeggiani
DFDaniele Francofonte
Daniele Francofonte
GDGiovanni Duro
Giovanni Duro